Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Return on Capital Employed for 10 consecutive years, with 0.57% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 7.0% to 0.57% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.57%, a 7.0% decrease, with the full-year FY2025 number at 0.48%, down 1.0% from a year prior.
  • Return on Capital Employed was 0.57% for Q4 2025 at Intellia Therapeutics, up from 0.58% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.23% in Q4 2021 to a low of 0.6% in Q2 2025.
  • A 5-year average of 0.41% and a median of 0.42% in 2023 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: rose 16bps in 2021, then dropped -19bps in 2022.
  • Intellia Therapeutics' Return on Capital Employed stood at 0.23% in 2021, then plummeted by -73bps to 0.39% in 2022, then decreased by -14bps to 0.45% in 2023, then dropped by -12bps to 0.5% in 2024, then decreased by -13bps to 0.57% in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Return on Capital Employed are 0.57% (Q4 2025), 0.58% (Q3 2025), and 0.6% (Q2 2025).